I'm a litigation reporter for Connecticut Law Tribune, covering litigation wins, verdict news, settlements, interesting cases, etc. Contact me with tips at [email protected].
CVS has been hit with at least three federal class actions, including two antitrust cases accusing CVS Caremark Corp. and other pharmacy benefit managers, the intermediaries between insurance companies and pharmacies, of price-fixing prescription drug reimbursement rates.
Class action lawsuits alleging violations of the Employee Retirement Income Security Act of 1974 are on the rise nationally against companies allegedly charging a higher premium for policyholders who use tobacco.
"Teva stifled would-be generic competitors to QVAR because the drug laws do not allow for generic substitution of a given drug-device combination unless the generic is approved for that specific drug-device combination," the complaint alleged.
Boehringer Ingelheim, one of 10 companies sent a warning letter by the FTC disputing the accuracy of patent listings in the FDA's Orange Book, was hit with an class action lawsuit, alleging that the company is using expired patents.
The health fund for the International Union of Operating Engineers is suing Eli Lilly, Novo Nordisk and Sanofi, as well as CVS Health and other PBMs, for "drastically" increasing the price of life-saving meds for "illicit profits."
The Connecticut-based health insurer was hit with another class action suit, alleging that once Cigna's PxDx algorithm denies claims, its medical doctors confirm the denials, without checking the patients' medical history.
In a lawsuit, a disabled worker alleges Electric Boat Corp. did not provide reasonable accommodations for his disabilities and he was ultimately fired for non-compliance with the company's post-COVID return-to-office policy.
When Cigna released its second-quarter financial performance on Aug. 5, 2021, its stock dropped by 13%, and Ferrie "realized an approximately 236% profit of $16,039.78 on his investment of $6,782.05," the complaint said.